Lilian founded Stern IR to provide differentiated investor and communications consulting to the healthcare industry, with a particular focus on biotechnology, including specialty pharmaceuticals, innovative diagnostics and tools, and vaccines. She got the idea that taking a strategic approach to investor relations was the best path to value creation, by crafting the IR program around the company’s financial goals. Throughout Stern IR’s history Lilian has committed to the key value that we do worthwhile work: contributing to human health by facilitating capital into the industry.
